Anthim, Obiltoxaximab SFL (obiltoxaximab) is an antibody pharmaceutical. Obiltoxaximab was first approved as Anthim on 2016-03-18. It is used to treat anthrax, crohn disease, and graft vs host disease in the USA. It has been approved in Europe to treat anthrax.
|Trade Name||Obiltoxaximab SFL|
|Indication||anthrax, crohn disease, graft vs host disease|
|Drug Class||Monoclonal antibodies: toxin as a target|